The Commission preliminarily concluded that the measure involves State resources, in particular due to the finding that German legislation lays down the prices that insurance funds (public and private) have to pay for pharmaceutical products and that the BAFA, a State authority, by granting exemptions from the mandatory rebates, ensures that these funds pay a higher price for the products in question.
30 3. DESCRIPTION OF THE MEASURE › 3.3. Grounds for initiating the procedure, Decision_act (EU) 2015/1300
In forcesince 27 Mar 2015